Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring
In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2019-10, Vol.21 (10), p.575-580 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 580 |
|---|---|
| container_issue | 10 |
| container_start_page | 575 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 21 |
| creator | Burckhardt, Marie-Anne Abraham, Mary B Mountain, Jennifer Coenen, Daina Paniora, Jaimee Clapin, Helen Jones, Timothy W Davis, Elizabeth A |
| description | In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people |
| doi_str_mv | 10.1089/dia.2019.0149 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2263317055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2299466541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-7736b1f4cb90ec28c24a6e22a28ee3b48b9b039cf79549b2f5f3562048f8f633</originalsourceid><addsrcrecordid>eNpd0ctq3DAUBmARWppbl90WQTfZeKqLZVvLMs0NEhLI7I0kH2UUbGkqyQ3zDHnpyCTtIisd0MfhP_wIfaNkRUknfw5OrRihckVoLQ_QERWirToh-adlZqSSVDSH6DilJ0JIyxn9gg455VxQyY7Qy_W0i-EvTOAzdh7fp73ZhhSMUyO-m7MJE6TlY7114xDB42eXt3iz3wGm-LdTGnIByg94swUX8b0qKCd8EcYxPDv_iB9mndywxzZEvA4-Oz-HOeHLcTYhAb4N3uUQizxFn60aE3x9f0_Q5uJ8s76qbu4ur9e_bipT0ueqbXmjqa2NlgQM6wyrVQOMKdYBcF13WmrCpbGtFLXUzArLRcNI3dnONpyfoLO3teXwPzOk3E8uGRhH5aEE6xkriLZEiEJ_fKBPYY6-hCtKyrppRE2Lqt6UiSGlCLbfRTepuO8p6ZeS-lJSv5TULyUV__1966wnGP7rf63wV7RJjjc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299466541</pqid></control><display><type>article</type><title>Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Burckhardt, Marie-Anne ; Abraham, Mary B ; Mountain, Jennifer ; Coenen, Daina ; Paniora, Jaimee ; Clapin, Helen ; Jones, Timothy W ; Davis, Elizabeth A</creator><creatorcontrib>Burckhardt, Marie-Anne ; Abraham, Mary B ; Mountain, Jennifer ; Coenen, Daina ; Paniora, Jaimee ; Clapin, Helen ; Jones, Timothy W ; Davis, Elizabeth A</creatorcontrib><description>In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people <21 years with type 1 diabetes (T1D). This study aimed to evaluate the effect of CGM on psychosocial outcomes in a T1D pediatric population-based sample.
Children with T1D, commencing CGM between June 2017 and January 2018, and their parents were recruited in a prospective cohort study in a tertiary pediatric hospital in Western Australia. Parents and children older than 12 years self-completed questionnaires at onset of CGM and 2 months later, on fear of hypoglycemia (FOH) and diabetes treatment satisfaction (DTS). Parents provided measures of sleep quality. Children completed the Gold hypoglycemia awareness score. Hemoglobin A1c (HbA1c) values were compared at baseline (BL) and follow-up (FU).
Sixty parents and 38 children provided measures at BL and FU. Parental total FOH decreased (mean score BL vs. FU; 50.0 vs. 44.3,
= 0.004) with reduction in the Worry subscore (28.2 vs. 24.2,
= 0.004). Furthermore, parental and child DTS increased. Parental sleep quality improved (
< 0.001) and overnight finger prick testing decreased (
< 0.001). Impaired hypoglycemic awareness decreased in children (26.3% vs. 10.5%,
= 0.031). HbA1c reduced from 8.4% (68 mmol/mol) to 8.1% (65 mmol/mol) (
= 0.036).
Introduction of subsidized CGM showed early improvement in psychosocial and glycemic outcomes in patients and their families in Western Australia. Ongoing evaluation is essential to assess whether equitable access to CGM will translate to sustained benefits for Australian T1D pediatric patients.</description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2019.0149</identifier><identifier>PMID: 31335192</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adolescent ; Blood Glucose - analysis ; Blood Glucose Self-Monitoring - economics ; Child ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 1 - economics ; Diabetes Mellitus, Type 1 - psychology ; Female ; Financing, Government ; Glucose monitoring ; Humans ; Hypoglycemia ; Hypoglycemia - chemically induced ; Hypoglycemia - psychology ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Insulin - administration & dosage ; Insulin - adverse effects ; Male ; Parents & parenting ; Parents - psychology ; Pediatrics ; Prospective Studies ; Sleep ; Subsidies ; Wearable Electronic Devices - economics ; Wearable Electronic Devices - psychology ; Western Australia</subject><ispartof>Diabetes technology & therapeutics, 2019-10, Vol.21 (10), p.575-580</ispartof><rights>Copyright Mary Ann Liebert, Inc. Oct 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-7736b1f4cb90ec28c24a6e22a28ee3b48b9b039cf79549b2f5f3562048f8f633</citedby><cites>FETCH-LOGICAL-c321t-7736b1f4cb90ec28c24a6e22a28ee3b48b9b039cf79549b2f5f3562048f8f633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31335192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burckhardt, Marie-Anne</creatorcontrib><creatorcontrib>Abraham, Mary B</creatorcontrib><creatorcontrib>Mountain, Jennifer</creatorcontrib><creatorcontrib>Coenen, Daina</creatorcontrib><creatorcontrib>Paniora, Jaimee</creatorcontrib><creatorcontrib>Clapin, Helen</creatorcontrib><creatorcontrib>Jones, Timothy W</creatorcontrib><creatorcontrib>Davis, Elizabeth A</creatorcontrib><title>Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description>In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people <21 years with type 1 diabetes (T1D). This study aimed to evaluate the effect of CGM on psychosocial outcomes in a T1D pediatric population-based sample.
Children with T1D, commencing CGM between June 2017 and January 2018, and their parents were recruited in a prospective cohort study in a tertiary pediatric hospital in Western Australia. Parents and children older than 12 years self-completed questionnaires at onset of CGM and 2 months later, on fear of hypoglycemia (FOH) and diabetes treatment satisfaction (DTS). Parents provided measures of sleep quality. Children completed the Gold hypoglycemia awareness score. Hemoglobin A1c (HbA1c) values were compared at baseline (BL) and follow-up (FU).
Sixty parents and 38 children provided measures at BL and FU. Parental total FOH decreased (mean score BL vs. FU; 50.0 vs. 44.3,
= 0.004) with reduction in the Worry subscore (28.2 vs. 24.2,
= 0.004). Furthermore, parental and child DTS increased. Parental sleep quality improved (
< 0.001) and overnight finger prick testing decreased (
< 0.001). Impaired hypoglycemic awareness decreased in children (26.3% vs. 10.5%,
= 0.031). HbA1c reduced from 8.4% (68 mmol/mol) to 8.1% (65 mmol/mol) (
= 0.036).
Introduction of subsidized CGM showed early improvement in psychosocial and glycemic outcomes in patients and their families in Western Australia. Ongoing evaluation is essential to assess whether equitable access to CGM will translate to sustained benefits for Australian T1D pediatric patients.</description><subject>Adolescent</subject><subject>Blood Glucose - analysis</subject><subject>Blood Glucose Self-Monitoring - economics</subject><subject>Child</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 1 - economics</subject><subject>Diabetes Mellitus, Type 1 - psychology</subject><subject>Female</subject><subject>Financing, Government</subject><subject>Glucose monitoring</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - chemically induced</subject><subject>Hypoglycemia - psychology</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - adverse effects</subject><subject>Male</subject><subject>Parents & parenting</subject><subject>Parents - psychology</subject><subject>Pediatrics</subject><subject>Prospective Studies</subject><subject>Sleep</subject><subject>Subsidies</subject><subject>Wearable Electronic Devices - economics</subject><subject>Wearable Electronic Devices - psychology</subject><subject>Western Australia</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0ctq3DAUBmARWppbl90WQTfZeKqLZVvLMs0NEhLI7I0kH2UUbGkqyQ3zDHnpyCTtIisd0MfhP_wIfaNkRUknfw5OrRihckVoLQ_QERWirToh-adlZqSSVDSH6DilJ0JIyxn9gg455VxQyY7Qy_W0i-EvTOAzdh7fp73ZhhSMUyO-m7MJE6TlY7114xDB42eXt3iz3wGm-LdTGnIByg94swUX8b0qKCd8EcYxPDv_iB9mndywxzZEvA4-Oz-HOeHLcTYhAb4N3uUQizxFn60aE3x9f0_Q5uJ8s76qbu4ur9e_bipT0ueqbXmjqa2NlgQM6wyrVQOMKdYBcF13WmrCpbGtFLXUzArLRcNI3dnONpyfoLO3teXwPzOk3E8uGRhH5aEE6xkriLZEiEJ_fKBPYY6-hCtKyrppRE2Lqt6UiSGlCLbfRTepuO8p6ZeS-lJSv5TULyUV__1966wnGP7rf63wV7RJjjc</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Burckhardt, Marie-Anne</creator><creator>Abraham, Mary B</creator><creator>Mountain, Jennifer</creator><creator>Coenen, Daina</creator><creator>Paniora, Jaimee</creator><creator>Clapin, Helen</creator><creator>Jones, Timothy W</creator><creator>Davis, Elizabeth A</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201910</creationdate><title>Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring</title><author>Burckhardt, Marie-Anne ; Abraham, Mary B ; Mountain, Jennifer ; Coenen, Daina ; Paniora, Jaimee ; Clapin, Helen ; Jones, Timothy W ; Davis, Elizabeth A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-7736b1f4cb90ec28c24a6e22a28ee3b48b9b039cf79549b2f5f3562048f8f633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Blood Glucose - analysis</topic><topic>Blood Glucose Self-Monitoring - economics</topic><topic>Child</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 1 - economics</topic><topic>Diabetes Mellitus, Type 1 - psychology</topic><topic>Female</topic><topic>Financing, Government</topic><topic>Glucose monitoring</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - chemically induced</topic><topic>Hypoglycemia - psychology</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - adverse effects</topic><topic>Male</topic><topic>Parents & parenting</topic><topic>Parents - psychology</topic><topic>Pediatrics</topic><topic>Prospective Studies</topic><topic>Sleep</topic><topic>Subsidies</topic><topic>Wearable Electronic Devices - economics</topic><topic>Wearable Electronic Devices - psychology</topic><topic>Western Australia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burckhardt, Marie-Anne</creatorcontrib><creatorcontrib>Abraham, Mary B</creatorcontrib><creatorcontrib>Mountain, Jennifer</creatorcontrib><creatorcontrib>Coenen, Daina</creatorcontrib><creatorcontrib>Paniora, Jaimee</creatorcontrib><creatorcontrib>Clapin, Helen</creatorcontrib><creatorcontrib>Jones, Timothy W</creatorcontrib><creatorcontrib>Davis, Elizabeth A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burckhardt, Marie-Anne</au><au>Abraham, Mary B</au><au>Mountain, Jennifer</au><au>Coenen, Daina</au><au>Paniora, Jaimee</au><au>Clapin, Helen</au><au>Jones, Timothy W</au><au>Davis, Elizabeth A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2019-10</date><risdate>2019</risdate><volume>21</volume><issue>10</issue><spage>575</spage><epage>580</epage><pages>575-580</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract>In April 2017, the Australian Government announced the full subsidy of continuous glucose monitors (CGM) to children and young people <21 years with type 1 diabetes (T1D). This study aimed to evaluate the effect of CGM on psychosocial outcomes in a T1D pediatric population-based sample.
Children with T1D, commencing CGM between June 2017 and January 2018, and their parents were recruited in a prospective cohort study in a tertiary pediatric hospital in Western Australia. Parents and children older than 12 years self-completed questionnaires at onset of CGM and 2 months later, on fear of hypoglycemia (FOH) and diabetes treatment satisfaction (DTS). Parents provided measures of sleep quality. Children completed the Gold hypoglycemia awareness score. Hemoglobin A1c (HbA1c) values were compared at baseline (BL) and follow-up (FU).
Sixty parents and 38 children provided measures at BL and FU. Parental total FOH decreased (mean score BL vs. FU; 50.0 vs. 44.3,
= 0.004) with reduction in the Worry subscore (28.2 vs. 24.2,
= 0.004). Furthermore, parental and child DTS increased. Parental sleep quality improved (
< 0.001) and overnight finger prick testing decreased (
< 0.001). Impaired hypoglycemic awareness decreased in children (26.3% vs. 10.5%,
= 0.031). HbA1c reduced from 8.4% (68 mmol/mol) to 8.1% (65 mmol/mol) (
= 0.036).
Introduction of subsidized CGM showed early improvement in psychosocial and glycemic outcomes in patients and their families in Western Australia. Ongoing evaluation is essential to assess whether equitable access to CGM will translate to sustained benefits for Australian T1D pediatric patients.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>31335192</pmid><doi>10.1089/dia.2019.0149</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2019-10, Vol.21 (10), p.575-580 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2263317055 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Blood Glucose - analysis Blood Glucose Self-Monitoring - economics Child Diabetes Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - economics Diabetes Mellitus, Type 1 - psychology Female Financing, Government Glucose monitoring Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemia - psychology Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Insulin - administration & dosage Insulin - adverse effects Male Parents & parenting Parents - psychology Pediatrics Prospective Studies Sleep Subsidies Wearable Electronic Devices - economics Wearable Electronic Devices - psychology Western Australia |
| title | Improvement in Psychosocial Outcomes in Children with Type 1 Diabetes and Their Parents Following Subsidy for Continuous Glucose Monitoring |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T19%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20in%20Psychosocial%20Outcomes%20in%20Children%20with%20Type%201%20Diabetes%20and%20Their%20Parents%20Following%20Subsidy%20for%20Continuous%20Glucose%20Monitoring&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Burckhardt,%20Marie-Anne&rft.date=2019-10&rft.volume=21&rft.issue=10&rft.spage=575&rft.epage=580&rft.pages=575-580&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/dia.2019.0149&rft_dat=%3Cproquest_cross%3E2299466541%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299466541&rft_id=info:pmid/31335192&rfr_iscdi=true |